The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma.

ABSTRACT:

Purpose of review

Dual immune checkpoint inhibition with ipilimumab plus nivolumab is currently the most effective, but also by far the most toxic treatment for advanced melanoma. Therefore, other combination partners that also lead to high and long-lasting responses but cause fewer adverse events were explored.

Recent findings

Relatlimab, a LAG-3 blocking antibody, was investigated in combination with nivolumab in a phase 2/3 randomized double-blind trial (RELATIVITY-047) and could demonstrate significantly improved progression-free survival in treatment-naive advanced melanoma patients compared with nivolumab monotherapy. While the safety profile is more favorable than that of ipilimumab plus nivolumab, no significant survival benefit has yet been demonstrated with the new

SUBMITTER: Albrecht LJ 

PROVIDER: S-EPMC10164023 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature